A Proven and Simple Screening Test to Accurately Detect Atherosclerosis and its Consequence, CVD
More and more data on the benefits of low oxLDL is appearing in the literature. The results of 100s of studies clearly show that low oxidized LDL correlates with a lower probability of a variety of disease states, most caused by atherosclerosis.
Testing for Oxidized LDL
National Screening Institute (NSI) has the exclusive worldwide rights to oxidized LDL and malondialdehyde (MDA)-modified LDL antibodies and corresponding technology developed by Professor Paul Holvoet at the University of Leuven, Belgium. Testing kits (MTP format) are manufactured under license by Mercodia (Uppsala, Sweden). The test is made available to the public in the USA by Quest Diagnostics.
What is Oxidized LDL?
Oxidized LDL is the atherogenic form of LDL cholesterol. Its concentration in blood is a powerful prognostic marker of atherosclerosis.
About Our Test
We offer antibodies to oxLDL and MDA-modified LDL that are superior to existing biomarkers in predicting atherosclerosis.
Read the latest research on the use of the oxLDL marker.
Read peer-reviewed papers that explain why oxidized LDL will become the biomarker of choice for annual screening and therapeutic monitoring of atherosclerosis and related disease.